Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort.

Oncotarget

Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD.
PMID: 29212164
Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07.

The underlying genetic cause of colorectal cancer (CRC) can be identified for 5-10% of all cases, while at least 20% of CRC cases are thought to be due to inherited genetic factors. Screening for highly penetrant mutations in genes...

Cite
Raskin L, Guo Y, Du L, et al. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017;8(55):93450-93463doi: 10.18632/oncotarget.18596.
Raskin, L., Guo, Y., Du, L., Clendenning, M., Rosty, C., Lindor, N. M., Gruber, S. B., & Buchanan, D. D. (2017). Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget, 8(55), 93450-93463. https://doi.org/10.18632/oncotarget.18596
Raskin, Leon, et al. "Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort." Oncotarget vol. 8,55 (2017): 93450-93463. doi: https://doi.org/10.18632/oncotarget.18596
Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07. PMID: 29212164; PMCID: PMC5706810.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes.

Molecular genetics & genomic medicine

DeRycke MS, Gunawardena S, Balcom JR, Pickart AM, Waltman LA, French AJ, McDonnell S, Riska SM, Fogarty ZC, Larson MC, Middha S, Eckloff BW, Asmann YW, Ferber MJ, Haile RW, Gallinger S, Clendenning M, Rosty C, Win AK, Buchanan DD, Hopper JL, Newcomb PA, Le Marchand L, Goode EL, Lindor NM, Thibodeau SN.
PMID: 28944238
Mol Genet Genomic Med. 2017 Jul 23;5(5):553-569. doi: 10.1002/mgg3.317. eCollection 2017 Sep.

BACKGROUND: Mutations in several genes predispose to colorectal cancer. Genetic testing for hereditary colorectal cancer syndromes was previously limited to single gene tests; thus, only a very limited number of genes were tested, and rarely those infrequently mutated in...

Cite
DeRycke MS, Gunawardena S, Balcom JR, et al. Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Mol Genet Genomic Med. 2017;5(5):553-569doi: 10.1002/mgg3.317.
DeRycke, M. S., Gunawardena, S., Balcom, J. R., Pickart, A. M., Waltman, L. A., French, A. J., McDonnell, S., Riska, S. M., Fogarty, Z. C., Larson, M. C., Middha, S., Eckloff, B. W., Asmann, Y. W., Ferber, M. J., Haile, R. W., Gallinger, S., Clendenning, M., Rosty, C., Win, A. K., Buchanan, D. D., Hopper, J. L., Newcomb, P. A., Le Marchand, L., Goode, E. L., Lindor, N. M., & Thibodeau, S. N. (2017). Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Molecular genetics & genomic medicine, 5(5), 553-569. https://doi.org/10.1002/mgg3.317
DeRycke, Melissa S, et al. "Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes." Molecular genetics & genomic medicine vol. 5,5 (2017): 553-569. doi: https://doi.org/10.1002/mgg3.317
DeRycke MS, Gunawardena S, Balcom JR, Pickart AM, Waltman LA, French AJ, McDonnell S, Riska SM, Fogarty ZC, Larson MC, Middha S, Eckloff BW, Asmann YW, Ferber MJ, Haile RW, Gallinger S, Clendenning M, Rosty C, Win AK, Buchanan DD, Hopper JL, Newcomb PA, Le Marchand L, Goode EL, Lindor NM, Thibodeau SN. Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Mol Genet Genomic Med. 2017 Jul 23;5(5):553-569. doi: 10.1002/mgg3.317. eCollection 2017 Sep. PMID: 28944238; PMCID: PMC5606870.
Copy Download .nbib Format: NLM
Risk Models for Breast Cancer and Their Validation.

Statistical science : a review journal of the Institute of Mathematical Statistics

Brentnall AR, Cuzick J.
PMID: 32226220
Stat Sci. 2020 Mar 03;35(1):14-30. doi: 10.1214/19-STS729.

Strategies to prevent cancer and diagnose it early when it is most treatable are needed to reduce the public health burden from rising disease incidence. Risk assessment is playing an increasingly important role in targeting individuals in need of...

Cite
Brentnall AR, Cuzick J. Risk Models for Breast Cancer and Their Validation. Stat Sci. 2020;35(1):14-30doi: 10.1214/19-STS729.
Brentnall, A. R., & Cuzick, J. (2020). Risk Models for Breast Cancer and Their Validation. Statistical science : a review journal of the Institute of Mathematical Statistics, 35(1), 14-30. https://doi.org/10.1214/19-STS729
Brentnall, Adam R, and Cuzick, Jack. "Risk Models for Breast Cancer and Their Validation." Statistical science : a review journal of the Institute of Mathematical Statistics vol. 35,1 (2020): 14-30. doi: https://doi.org/10.1214/19-STS729
Brentnall AR, Cuzick J. Risk Models for Breast Cancer and Their Validation. Stat Sci. 2020 Mar 03;35(1):14-30. doi: 10.1214/19-STS729. PMID: 32226220; PMCID: PMC7100774.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries